Journal article
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
Abstract
BACKGROUND: Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when added to angiotensin-converting-enzyme (ACE) inhibitors in patients with chronic heart failure (CHF). We aimed to find out whether these drugs improve clinical outcome.
METHODS: Between March, 1999, and November, 1999, we enrolled 2548 patients with New York Heart Association …
Authors
McMurray JJ; Östergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA; Investigators and Committees FTC
Journal
The Lancet, Vol. 362, No. 9386, pp. 767–771
Publisher
Elsevier
Publication Date
September 2003
DOI
10.1016/s0140-6736(03)14283-3
ISSN
0140-6736
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzimidazolesBiphenyl CompoundsCardiac Output, LowCardiovascular DiseasesComorbidityDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHospitalizationHumansMalePlacebosTetrazolesTreatment OutcomeVentricular Dysfunction, Left